Crucell and Aeras Start TB Vaccine Trial
Posted on: Thursday, 26 October 2006, 15:01 CDT
Dutch biotechnology company Crucell has started the phase I clinical trial of the AdVac-based tuberculosis vaccine it is developing in partnership with The Aeras Global TB Vaccine Foundation.
The clinical trial will test the vaccine in a dose-escalation trial involving 24 healthy volunteers. The main parameters under examination will be safety, tolerability and immunogenicity.
"The start of this phase I trial is important to our overall goal of developing a new vaccine to help eliminate the current TB pandemic," added Dr Jerald Sadoff, CEO of Aeras.
The second-generation Ad35 vector applied in the Crucell-Aeras TB program is extremely suitable for vaccine production on PER.C6 cell culture at scale. The production scale potential of the PER.C6 cell line has been demonstrated in an unprecedented successful bioreactor run. Such highly productive systems are particularly important in the case of poverty-related diseases such as HIV, malaria and TB, when 10-100 millions of doses need to be manufactured while keeping costs relatively low.
Source: Datamonitor
Related Articles
- Crucell and Aeras Initiate Phase I Tuberculosis Vaccine Trial in Kenya
- Increased Flu and Exotic Disease Vaccine Trials Thrive at Passport Health
- Australian Company Announces Successful Results of Bird Flu Vaccine Trial
- IDM Closes Enrollment to Its EP-2101 Therapeutic Vaccine Trial in Patients With Non-Small Cell Lung Cancer
- Tanzania to Start AIDS Vaccine Trial Next March
- South Africa to host phase II AIDS vaccine trials
- S.Africa to host phase 2 AIDS vaccine trials
- French, Chinese Firms to Conduct Bird Flu Vaccine Trials in Thailand
- Thailand Requests Japanese Cooperation on Bird Flu Vaccine Trials
- China's Phase One AIDS Vaccine Trial Nears End
 |
 |
User Comments (0)
RSS Feeds